Grant Zeng, CFA
Research analyst, CFA, biotech, small-cap

Soligenix: 3 Platform Technologies Generate A Diversified Pipeline Targeting Multiple Indications

Soligenix (OTCQB:SNGX) is a development stage biopharmaceutical company focused on developing products for cancer supportive care, serious gastrointestinal (NYSE:GI) diseases, as well as vaccine technology in the areas of biodefense and infectious disease. SNGX holds three platform technologies: the SGX94 platform, the platform of oral beclomethasone 17, 21-dipropionate (oral BDP), and the ThermoVax platform technology. Based on these three platforms, SNGX has developed a diversified pipeline.

(click to enlarge)(click to enlarge)

The SGX94 Platform Has Potential To Targets Multiple Indications

SGX94 belongs to a new class of compounds called Innate Defense Regulators (IDRs). The SGX94 IDR platform represents a novel and innovative approach to therapeutically modulating the immune system by targeting the innate

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details